CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
hMSCsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02625246
NCT02625246Phase 1Completed
CompareCT.gov

A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis

Marilyn Glassberg·interventional·Posted Dec 9, 2015·Updated Aug 28, 2019

In Brief

A Phase 1 clinical trial evaluating hMSCs for Bronchiectasis. Completed, enrolled 6 participants across 1 site.

Detailed Summary

To demonstrate the safety of bone marrow-derived allogeneic human Mesenchymal Stem Cells (hMSCs) in patients with bronchiectasis receiving standard of care therapy, and to explore treatment efficacy

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiectasis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 9, 2015
Enrollment StartFeb 4, 2016
Primary CompletionMay 15, 2019
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.6 years ago

Interventions

hMSCsbiological

intravenous infusion of bone marrow-derived allogeneic stem cells